Recent review articles about ovarian cancer (InTextoResearch)


InTextoResearch, agency for scientific information


InTextoResearch informs on the most recent review articles about
ovarian cancer:

Strategies to examine new compounds for intraperitoneal use in ovarian
cancer.
Markman M.
Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:33-5.

Can carboplatin replace cisplatin for intraperitoneal use?
Fujiwara K.
Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:29-32.

Ovarian cancer in the proteomics era.
Annunziata CM, Azad N, Dhamoon AS, Whiteley G, Kohn EC.
Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:1-6.

Mechanisms of chemoresistance and poor prognosis in ovarian clear cell
carcinoma.
Itamochi H, Kigawa J, Terakawa N.
Cancer Sci. 2008 Apr;99(4):653-8.

Risk factors for ovarian cancer: an overview with emphasis on hormonal
factors.
Salehi F, Dunfield L, Phillips KP, Krewski D, Vanderhyden BC.
J Toxicol Environ Health B Crit Rev. 2008 Mar;11(3-4):301-21.

The clinical management of BRCA1 and BRCA2 mutation carriers.
Gulati AP, Domchek SM.
Curr Oncol Rep. 2008 Jan;10(1):47-53.

Neuroectodermal ovarian tumors: a brief overview.
Morovic A, Damjanov I.
Histol Histopathol. 2008 Jun;23(6):765-71.

Pathogenesis of ovarian cancer: lessons from morphology and molecular
biology and their clinical implications.
Kurman RJ, Shih IeM.
Int J Gynecol Pathol. 2008 Apr;27(2):151-60.

Histologic subtypes of ovarian carcinoma: an overview.
Soslow RA.
Int J Gynecol Pathol. 2008 Apr;27(2):161-74.

Grading of ovarian cancer: a histotype-specific approach.
Malpica A.
Int J Gynecol Pathol. 2008 Apr;27(2):175-81.

Uterine tumors resembling ovarian sex cord tumors: an update.
Czernobilsky B.
Int J Gynecol Pathol. 2008 Apr;27(2):229-35.

Intraperitoneal chemotherapy in ovarian cancer: an update.
Runowicz CD.
Cancer J. 2008 Jan-Feb;14(1):7-9.

Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT
become a promising treatment against ovarian cancer?
Nawa A, Tanino T, Luo C, Iwaki M, Kajiyama H, Shibata K, Yamamoto E,
Ino K, Nishiyama Y, Kikkawa F.
Anticancer Agents Med Chem. 2008 Feb;8(2):232-9.

Immunotherapy opportunities in ovarian cancer.
Chu CS, Kim SH, June CH, Coukos G.
Expert Rev Anticancer Ther. 2008 Feb;8(2):243-57.

Targeting signaling pathways in ovarian cancer.
Reibenwein J, Krainer M.
Expert Opin Ther Targets. 2008 Mar;12(3):353-65.

Angiogenesis as a strategic target for ovarian cancer therapy.
Spannuth WA, Sood AK, Coleman RL.
Nat Clin Pract Oncol. 2008 Apr;5(4):194-204.

Giant abdominal tumor of the ovary.
Ueda S, Yamada Y, Tsuji Y, Kawaguchi R, Haruta S, Shigetomi H,
Kanayama S, Yoshida S, Sakata M, Sado T, Kitanaka K, Kobayashi H.
J Obstet Gynaecol Res. 2008 Feb;34(1):108-11.

Cancer surveillance based on imaging techniques in carriers of BRCA1/2
gene mutations: a systematic review.
Bermejo-Pérez MJ, Márquez-Calderón S, Llanos-Méndez A.
Br J Radiol. 2008 Mar;81(963):172-9.

Discovery and application of protein biomarkers for ovarian cancer.
Gagnon A, Ye B.
Curr Opin Obstet Gynecol. 2008 Feb;20(1):9-13.

Early events in the pathogenesis of epithelial ovarian cancer.
Landen CN Jr, Birrer MJ, Sood AK.
J Clin Oncol. 2008 Feb 20;26(6):995-1005.


(contact at InTextoResearch: Marc Lacroix, Baelen, Wallonia, Belgium -
scimedweb@xxxxxxxx)
.